Drug news

Flutiform enters Phase III for COPD

Read time: 1 mins

Last updated:19th Sep 2013

Published:19th Sep 2013

Source: Pharmawand

Mundipharma Research Limited announced commencement of the EFFECT (Efficacy of Fluticasone propionate/FormotErol in COPD Treatment) study which is designed to investigate the superiority of Flutiform compared with formoterol based on the annual rate of moderate and severe COPD exacerbations over a 52-week treatment period.

Flutiform is currently marketed for bronchial Asthma in 12 European countries, and is approved in Israel, Australia and Hong Kong.

Learning Zone Homepage

Respiratory Care

The Respiratory Care Learning Zone contains essential information on Inhaled Therapies in Asthma and COPD and its Management. The Learning Zone also has an Educational Resources section which features slide kits, congress news and webinars and videos relevant to asthma and COPD.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Topline results from phase II PRECEDENT study of dalzanemdor (SAGE 718) in the treatment of mild cognitive impairment in Parkinson’s disease

Sage Therapeutics, Inc. announced topline results from PRECEDENT, a double-blind, placebo-controlled Phase II study of the investigational oral medicine dalzanemdor (SAGE-718) in people with mild cognitive impairment (MCI) in Parkinson’s Disease (PD)

1 mins

Drug news

Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity

Eli Lilly and Company announced positive topline results of the SURMOUNT-OSA phase III clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints

2 min

Drug news

Positive phase III topline results from Study 501 evaluating lumateperone as adjunctive therapy in patients with major depressive disorder

Intra-Cellular Therapies, Inc. a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced positive topline results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

2 min

See all news